Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Overview
Date Founded

2010

Headquarters

10880 WILSHIRE BOULEVARD,, SUITE 2150, LOS ANGELES, CA, 90024

Type of Company

Public

Employees (Worldwide)

272

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Contact Data
Trying to get in touch with decision makers at Puma Biotechnology, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Financial Officer & Principal Accounting Officer

Chief Commercial Officer

Chief Medical & Scientific Officer

Senior Vice President, Regulatory Affairs, Medical Writing & Project Management

Owner Partner

Senior Director

Senior Director

Board of Directors

Founder at Puma Biotechnology, Inc.

Managing Member at Drayton Investments LLC

Director at Puma Biotechnology, Inc.

Executive Vice President, US Commercial at Jazz Pharmaceuticals, Inc.

Senior Vice President & Chief Medical Officer at Constellation Pharmaceuticals, Inc.

Professional at Puma Biotechnology, Inc.

Paths to Puma Biotechnology, Inc.
Potential Connections via
Relationship Science
You
Puma Biotechnology, Inc.
Owners & Shareholders
Details Hidden

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

Details Hidden

PFM generally uses bottom-up analysis to identify trends, investment themes and core investment opportunities across asset classes and geographies in a wide range of investment instruments. The firm may invest in various industries or sectors, including, but not limited to, communications and media, consumer, energy, financials, healthcare, industrials, materials, technology and utilities. Their main investment strategies include diversified global and healthcare. PFM seeks to identify out- and under-performing companies that have the widest expectation gaps relative to consensus. In some cases, they may apply a catalyst-driven investment approach to express their fundamental view with respect to a company. PFM may also engage in top-down macro-economic analysis to identify opportunities, whether on a directional or relative value basis, across a wide range of global markets and investment instruments. They may consider economic, political and financial market conditions in seeking to identify attractive investment opportunities. The firm invests in and trades a wide range of investment instruments, including securities, options, ETFs, futures, currencies, derivatives, debt instruments and other assets that are financial instruments. They take both long and short positions in such investment instruments.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Recent Transactions
Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onPuma Biotechnology, Inc. issued Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Auditor

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Managing Director

Advised onPuma Biotechnology, Inc. issued Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Clients

CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Cigna is more than a health insurance company. They are a global health service company. Cigna works with employers and organizations around the world helping employees stay healthy and on the job. They work closely with brokers and consultants to develop innovative programs, help individuals and families improve their health, well-being and sense of security—and lower their medical costs. And, Cigna provides access to a global network of local physicians and hospitals—as well as 24/7/365 live customer service.

Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Key Stats and Financials As of 2018
Market Capitalization
$1.47B
Total Enterprise Value
$759M
Earnings Per Share
$-2.99
Revenue
$251M
Net Profit
$-114M
EBITDA
$-87.3M
EBITDAMargin
-34.78%
Total Debt
$152M
Total Equity
$34.3M
Enterprise Value Sales
3.02x
TEVNet Income
-6.68x
Debt TEV
0.2x
Investors
Details Hidden

Oxford Finance Corporation operates as a specialty financial services company. It offers senior secured, asset-based, equipment, and working capital loans. The company primarily serves public and private life science companies. Oxford Finance Corporation was founded in 2002 and is headquartered in Alexandria, Virginia with additional offices in Massachusetts and California. Oxford Finance Corporation operates as a subsidiary of Sumitomo Corporation of America

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR's or its affiliates' central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

CaligorRx, Inc. Medical Products & Equipment | Secaucus, NJ

Caligor RX, Inc. provides clinical trial supply and logistics services. It manages the regulatory, logistics, and supply chain challenges of sourcing, storing, and distributing investigational drugs for comparator clinical trials and unlicensed medicines for expanded access programs. The firm serves pharmaceutical and biotechnology companies. The company is headquartered in Secaucus, NJ.

Competitors
Seattle Genetics, Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Puma Biotechnology, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Puma Biotechnology, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Puma Biotechnology, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/puma-biotechnology-inc-1895937
  • https://relationshipscience.com/organization/puma-biotechnology-inc-1895937